Lumos Pharma Inc

Lumos Pharma — Investor Presentation (June 2024)

44 slides from Lumos Pharma's investor presentation, Jun 5, 2024

  1. Slide 1: Corporate & Clinical Overview May 2024

    1 Corporate & Clinical Overview May 2024

  2. Slide 2: Forward Looking Statements

    2 Forward Looking Statements This presentation contains forward-looking statements of Lumos Pharma, Inc. that involve substantial risks and uncertainties. All such statements contained in this presentation are forward- looking statements within the meaning of The Private Securities Litigation Reform

  3. Slide 3: Investment Thesis

    3 • Positive End-of-Phase 2 meeting with FDA held early Q2 2024 regarding Phase 3 program • Initiation of Phase 3 trial anticipated Q4 2024 • PEM strategy de-risks patient selection, identifying likely LUM-201 responders*** • Phase 2 trials met all primary and secondary endpoints • Phase 2 data demo

  4. Slide 4: Management – Significant Clinical Development and Commercial Experience

    4 Management – Significant Clinical Development and Commercial Experience Richard Hawkins Chairman & CEO Developed Growth Hormone (GH) Receptor Antagonist for Acromegaly at Sensus (sold to Pfizer). Built one of the first contract recombinant protein manufacturing facilities (Covance Biotechnology).

  5. Slide 5: Market Opportunity for Oral LUM-201

    5 Market Opportunity for Oral LUM-201 ~$4.7B 2022 Market by Indication (Gross, including China, US$ MM) Low compliance Early discontinuation Low referral for moderate PGHD 75% 25% Interview Question: If a daily oral secretagogue and a weekly rhGH injectable product were both FDA-approved and availab

  6. Slide 6: LUM-201 Program Pipeline

    6 LUM-201 Program Pipeline Study Pre-Clinical Phase 1 Phase 2 Phase 3 Status LUM-201 (Ibutamoren) in Moderate PGHD Dose-finding trial Phase 2 Topline Data met endpoints (Nov 2023) Positive End-of-Phase 2 meeting with FDA Long-term extension Long-term extension study for OraGrowtH Trials: Ongoing enr

  7. Slide 7: FDA End-of-Phase 2 Meeting Update

    7 FDA End-of-Phase 2 Meeting Update Positive, constructive meeting with ~30 FDA staff in attendance Acknowledged that we are not a GH product – but a novel growth promotor Tone was collaborative and focused on approaches for a Phase 3 pivotal trial FDA suggested that a placebo-controlled Phase 3 tri

  8. Slide 8: LUM-201 Augments Endogenous Pulsatile Release of Growth Hormone

    8 Figure 1: Advanced Therapies in Pediatric Endocrinology and Diabetology. Endocr Dev. Basel, Karger, 2016 Figure 2: : Cassorla, F, et al. IMPE, March 2023; GH concentrations sampled every 10 minutes for 12-hour period at baseline and after six months of daily oral treatment * Merck 020 study LUM-20

  9. Slide 9: LUM-201 Restores Natural Growth Hormone & IGF-1 Secretion

    9 LUM-201 Restores Natural Growth Hormone & IGF-1 Secretion • LUM-201 is an oral GH secretagogue* • Acts on specific receptors in hypothalamus and pituitary to stimulate release of GH1 • Increases the amplitude of natural pulsatile GH secretion, 2,3 normalizing GH levels after 6 months on therapy4 •

  10. Slide 10: PEMs Enrich Trials for Patients Likely to Respond to LUM-201

    10 PEMs Enrich Trials for Patients Likely to Respond to LUM-201* Responders to LUM-2012 Non-Responders to LUM-201 Moderate PGHD PEM-Positive ~60% of total PGHD population1 Severe PGHD PEM-Negative ~40% of total PGHD population Predictive Enrichment Marker Positive (PEM+) • Baseline IGF-1 > 30 ng/ml

  11. Slide 11: Phase 3 Trial Design Options Discussed with the FDA

    11 Phase 3 Trial Design Options Discussed with the FDA Lumos Submitted Non-Inferiority Study • LUM-201 vs rhGH control • 12-month duration • Non-inferiority margin o The lower bound of non-inferiority margin must be above the clinically meaningful AHV growth rate • LUM-201 vs placebo • 12-month dura

  12. Slide 12: Proposed Placebo-Controlled Phase 3 Trial Design

    12 Confidential • 12-month double-blind placebo-controlled trial in PEM+ PGHD patients o All placebo subjects cross over to LUM-201 at 6 months • ~150 subjects in global study across ~80-100 sites o 2:1 randomization – 1.6 mg/kg/day LUM-201:Placebo • Co-primary endpoints at 12 months: o LUM-201 arm

  13. Slide 13: Proposed Placebo-Controlled Phase 3 Trial Design

    13 12-month, 2:1 randomization, double-blind, single arm cross-over design with all placebo patients switched to LUM-201 at 6 months, who then continue for an additional 6 months on treatment Screening Up to 60 days LUM-201 1.6 mg/kg/day 12 months N ~100 Placebo control 6 months N= approximately 40

  14. Slide 14: Key Milestones Provide Clear Regulatory Pathway

    14 Key Milestones Provide Clear Regulatory Pathway • Positive End-of-Phase 2 meeting with FDA supportive of registrational path forward o FDA recognized LUM-201, a growth hormone secretagogue, as a novel growth promoter o FDA acknowledged the use of a placebo-controlled clinical trial design as an a

  15. Slide 15: OraGrowtH210 Trial: Phase 2 Trial in Naïve Moderate PGHD

    15 OraGrowtH210 Trial: Phase 2 Trial in Naïve Moderate PGHD n = ~20 Daily rhGH injection n = ~20 LUM-201: 3.2 mg/kg/day n = ~20 LUM-201: 1.6 mg/kg/day n = ~20 LUM-201: 0.8 mg/kg/day • n = 82 • PEM(+) PGHD subjects • Inclusion: stim GH ≥ 5 ng/ml and baseline IGF-1 >30 ng/ml • rhGH treatment naïve • ~

  16. Slide 16: PEM Test Enriches the Responder Population & Yields Highly Reproducible Results

    16 • PEM test ensures patients enrolled in the study are capable of secreting GH in response to a single-dose of LUM-201 • PEM test is highly reproducible • PEM-positive criteria: o PGHD patients with baseline IGF-1 > 30 ng/ml o Peak stimulated GH ≥ 5 ng/ml after a single 0.8 mg/kg dose of LUM-201 n

  17. Slide 17: OraGrowtH210: LUM-201 Growth Comparable to Multiple 12-Month Historical Datasets

    17 OraGrowtH210: LUM-201 Growth Comparable to Multiple 12-Month Historical Datasets *Daily Genotropin control group for Somatrogon Ph3 dosed at 0.034 mg/kg/day (equates to 0.24 mg/kg/wk); subjects were stratified based on GH production during a standard stim test. JCEM Volume 107, Issue 7, July 2022

  18. Slide 18: Full OraGrowtH210 Data at 12 Months

    18 AHV at 6 & 12 Months on LUM-201 (1.6 mg/kg/day) Full OraGrowtH210 Data at 12 Months Demonstrate Significant Increase in Growth from Baseline, Durable Effect to 1 year, and Confirm Optimal LUM-201 Dose of 1.6 mg/kg/day A n n u a li z e d H e ig h t V e lo c it y (c m /y r) AHV at 12 Months on Trea

  19. Slide 19: OraGrowtH212 Trial: PK/PD Trial in Naïve Moderate PGHD

    19 • n = 22 • Open-label study • Moderate PGHD patients • rhGH-treatment naïve • Dosing to near-adult height • Single, specialized clinical site in Santiago, Chile • Q10 minute GH sampling for 12 hours OraGrowtH212 Trial: PK/PD Trial in Naïve Moderate PGHD Study Endpoints: • Assess LUM-201 effect on

  20. Slide 20: Full OraGrowtH212 Data at 12 Months

    20 Full OraGrowtH212 Data at 12 Months Demonstrate Meaningful Growth from Baseline and Durable Effect to 1 year on Treatment Error bars represent Standard Error Measurement. AHV at 6 & 12 Months on Treatment (Combined 1.6 & 3.2 mg/kg/day LUM-201) vs Baseline AHV at 12 Months on Treatment vs Baseline

  21. Slide 21: OraGrowtH212: LUM-201 Augments GH Pulses, Increases IGF-1 and Growth Rate

    21 0 200 400 600 800 0 1 2 3 4 5 Patient B Time (min) S e ru m G ro w th H o rm o n e (n g /m l) Baseline Month 6 Patient A Serum GH at Baseline & at 6 months on LUM-201 OraGrowtH212: LUM-201 Augments GH Pulses, Increases IGF-1 and Growth Rate Month 6 for Patient A (3.2 mg/kg/day) Baseline 6 months

  22. Slide 22: LUM-201 Achieved Similar Growth to Injectable rhGH with ~20% of GH Levels

    22 By Increasing Endogenous 24-hour Pulsatile GH Secretion, LUM-201 Achieved Similar Growth to Exogenous Injectable rhGH, with Only ~20% of GH Concentration Levels • LUM-201 increased GH to levels similar to a normal growing child • LUM-201 induced the release of ~20% of the GH from a 34 mcg/kg/day

  23. Slide 23: LUM-201 Normalizes IGF-1 SDS with Durable Effect out to 12 Months

    23 LUM-201 Normalizes IGF-1 SDS with Durable Effect out to 12 months OraGrowtH210 and OraGrowtH212 Topline Phase 2 Data Bars represent sample mean, and error bars represent Standard Error of the Mean baseline 0.8 1.6 3.2 rhGH -2 -1 0 1 2 9 0.74 0.14 -0.21 11 -0.48 41 -1.38 210 IGF-1 SDS 12m data PP1

  24. Slide 24: LUM-201 Data Suggests Sustained Durability of Response vs SOC rhGH

    24 LUM-201 Data Suggests Sustained Durability of Response vs SOC rhGH OraGrowtH210 & OraGrowtH212 Combined (1.6 and 3.2 mg/kg LUM-201) • Preliminary data demonstrated LUM-201 AHV durable to 24 months • More moderate year 2 AHV decline than rhGH likely due to LUM-201 restoration of GH and IGF-1 to no

  25. Slide 25: Favorable Investigational Safety Profile from Topline OraGrowtH Trial Data

    25 Favorable Investigational Safety Profile from Topline OraGrowtH Trial Data Two subjects had an SAE between PEM dose and randomized dose: 1 subject in LUM-201 0.8 mg/kg cohort and 1 subject in rhGH cohort • Both SAEs likely due to effect of fasting prior to administration of PEM dose Favorable Inv

  26. Slide 26: Summary of Topline and Updated Phase 2 Data

    26 Summary of Topline and Updated Phase 2 Data • Topline Phase 2 data met all primary and secondary endpoints • PEM test was reproducible and predicted response to LUM-201 • Oral LUM-201 significantly increased growth rates from baseline • LUM-201 restored normal GH secretion and IGF-1 levels throug

  27. Slide 27: Commercial Appeal of Oral LUM-201

    27 Commercial Appeal of Oral LUM-201 o Oral therapy preferred over injections for pediatric GHD and should expand the market1,2 o LUM-201 growth rates more stable vs rhGH over time3,4,5 o Daily rhGH growth rate declines ~20% from year 1 to year 2 in moderate PGHD population4,5 o Year 1 to year 2 gro

  28. Slide 28: LUM-201: Exclusivity and Barriers with Orphan Designation and IP

    28 LUM-201: Exclusivity and Barriers with Orphan Designation and IP * ODD exclusivity from date of drug approval with potential pediatric extensions GHD = Growth Hormone Deficiency NAFLD = Non-alcoholic Fatty Liver Disease Orphan Drug Designation • Orphan Drug Designation (ODD) granted in US & EU fo

  29. Slide 29: Lumos Pharma Financial Information as of March 31, 2024

    29 Lumos Pharma Financial Information as of March 31, 2024 Values in USD Cash, Equivalents & Short-term Investments $23.2M Debt $0 Shares Outstanding 8.1M Cash Runway Through 3Q 2024 Fiscal Year End December 31 Cash, cash equivalents, & short-term investments to support operations through 3Q 2024, i

  30. Slide 30: Investment Thesis

    30 • Positive End-of-Phase 2 meeting with FDA held early Q2 2024 regarding Phase 3 program • Initiation of Phase 3 trial anticipated Q4 2024 • PEM strategy de-risks patient selection, identifying likely LUM-201 responders*** • Phase 2 trials met all primary and secondary endpoints • Phase 2 data dem

  31. Slide 31: Supplementary Materials

    Supplementary Materials

  32. Slide 32: rhGH Market Gross Sales – by Indication and by Region

    32 rhGH Market Gross Sales – by Indication and by Region 2022 rhGH Global Sales by Indication (Gross, Including China, US$ MM) 2022 rhGH Global Sales by Region (Gross, US$ MM) PGHD $1,490 ISS $915 AGHD $540 Turner $710 PWS $240 SGA $250 Other * $530 $4.7B US $1,820 EU5 $540 Japan $395 S. Korea $185

  33. Slide 33: LUM-201 History

    33 LUM-201 History Developed LUM-201 to improve health span >1,200 subjects studied, primarily elderly adults √ GH Levels ↑ √ IGF levels ↑ √ Consistent improvements in body composition1 √ Sustained Effect to 24 months1 • Discontinued for strategic reasons 1 Nass 2008 Ann Intern Med 2Performed by Lum

  34. Slide 34: LUM-201 Potential in Obesity and Cardiometabolic Indications

    34 LUM-201 Potential in Obesity and Cardiometabolic Indications GLP1-Ra/LUM-201 Combination to Improve Quality of Weight Loss • GH secretion is blunted in obesity • Growth hormone deficient adults have similar metabolic and body composition consequences as normal obese subjects • Increases in GH and

  35. Slide 35: Endogenous GH Secretion is Blunted in Obesity

    35 Endogenous GH Secretion is Blunted in Obesity1 Endogenous GH levels are reduced in a stepwise manner with disease severity . . . 1Utz, et al, “Androgens May Mediate a Relative Preservation of IGF-I Levels in Overweight and Obese Women Despite Reduced Growth Hormone Secretion, J Clin Endocrinol Me

  36. Slide 36: Growth Hormone Plays an Important Role in Metabolic Function and Cardiovascular Health

    36 Growth Hormone Plays an Important Role in Metabolic Function and Cardiovascular Health Beyond its effects on bone growth and musculoskeletal anabolism, GH plays an important role in the regulation of lipid metabolism, body fat distribution, inflammation and vascular health1 1Stanley, Grinspoon, “

  37. Slide 37: GH Increases IGF-1 Production: Skeletal Muscle Growth Modulated by IGF-1 and Myostatin

    37 GH increases IGF-1 Production: Growth of Skeletal Muscle is Modulated by the Combined Actions of IGF-1 and Myostatin 1Ahima and Park Endocrinol Metab 2015, 30:235-245 2Suh et al, PNAS 2020, 117(9):4910-4920 3Nass 2008 Ann Intern Med • IGF-1 and myostatin have contrasting roles in regulating skele

  38. Slide 38: GH Treatment Effects on AGHD, Obesity, and MASH

    38 GH Treatment Effects on Adult Growth Hormone Deficiency (AGHD), Obesity, and MASH 1Stanley, Grinspoon, “Effects of growth hormone–releasing hormone on visceral fat, metabolic, and cardiovascular indices in human studies”, Growth Hormone & IGF Research 25 (2015) 59-65 2Growth hormone reverses nona

  39. Slide 39: Strong Evidence with an Injectable GHRH Analog

    39 Strong Evidence with an Injectable GHRH Analog1 • Tesamorelin (analog of GHRH) is an injectable peptide that stimulates GH Release o Different biological mechanism than LUM-201 o Approved to treat HIV Lipodystrophy • 52-week study in 60 abdominally obese subjects (Standard GH stim test ≤ 9 ug/L)

  40. Slide 40: Pulsatile Delivery of GH Almost Doubles the Rate of Lipolysis in Obese Subjects

    40 Pulsatile Delivery of GH Almost Doubles the Rate of Lipolysis in Obese Subjects vs. Continuous Infusion of GH1 Study Objective: Mimic normal GH physiology to determine treatment effects in obese subjects Study Design • 9 Obese subjects were dosed rhGH 0.015 mg/kg/day for three days, switched as f

  41. Slide 41: Highlights from LUM-201 Adult Studies

    Highlights from LUM-201 Adult Studies 41

  42. Slide 42: Functional Benefits and Consistent PD Effects Observed in Multiple Adult Disease Settings

    42 Functional Benefits and Consistent PD Effects Observed in Multiple Adult Disease Settings Setting Treatment Duration1 Increase in Serum IGF-1 P-Value N1 Key Findings Healthy Elderly 12 months 50% <0.001 43 LUM-201 restored and maintained GH and IGF-1 concentrations back to lower limit of normal f

  43. Slide 43: LUM-201 PD and Clinical Effects Are Durable in Healthy Elderly

    43 LUM-201 PD and Clinical Effects Are Durable in Healthy Elderly1 Normalized IGF-1 levels and improved fat free mass from baseline Healthy elderly adults treated with 25mg LUM-201 once daily for up to 24 months 1Nass 2008 Ann Intern Med (Supplemental Information) Barred data represent 95% Confidenc

  44. Slide 44: Treatment With LUM-201 Increased Nitrogen Balance In Catabolic State

    44 Treatment With LUM-201 Increased Nitrogen Balance In Catabolic State1 1 Murphy et al J. Clin. Endocrinol. Metab. 1998 2 P=0.001 3 P<0.005 AUC: Area Under the Curve Placebo Placebo LUM-201 25 mg Caloric Restriction Normal Diet Placebo Placebo LUM-201 25 mg Caloric Restriction Study Design: Double-

Lumos Pharma — Investor Presentation (June 2024) on 6ix